CANCER EARLIER DIAGNOSIS – POSSIBILITIES AND CONSEQUENCES

FOUNDATION FOR SCIENCE AND TECHNOLOGY DEBATE – 11 JULY 2017

Harpal Kumar, CEO CANCER RESEARCH UK



KEY POINTS: CANCER EARLIER DIAGNOSIS

The imperative

The possibilities


Consequences for patients and individuals

Implications for the health system



THE IMPORTANCE OF EARLY DIAGNOSIS


LATE DIAGNOSIS = POORER OUTCOME



Data for people diagnosed in England in 2014 Source: ONS/PHE, Cancer survival by stage at diagnosis for England (experimental statistics)




THE IMPORTANCE OF EARLY DIAGNOSIS



Source: National Cancer Intelligence Network. Stage Breakdown by CCG 2014. London: NCIN; 2016.

LATE DIAGNOSIS = POORER OUTCOME



CANCER RESEARCH UK

EARLIER DIAGNOSIS HAS THE POTENTIAL TO REDUCE TREATMENT COSTS

The average cost	The average cost	The average cost
of Stage 1 lung	of Stage 1 colon	of Stage 1 rectal
cancer is	cancer is	cancer is
estimated at	estimated at	estimated at
£7,952	£3,373	£4,449
The average cost	The average cost	The average cost
The average cost of Stage 4 lung	The average cost of Stage 4 colon	The average cost of Stage 4 rectal
Ŭ		Ű
of Stage 4 lung	of Stage 4 colon	of Stage 4 rectal



KEY POINTS: CANCER EARLIER DIAGNOSIS

The imperative

The possibilities

Consequences for patients and individuals

Implications for the health system




THE POSSIBILITIES FOR EARLIER DIAGNOSIS

- Screening uptake
- Investment in additional capacity
- System efficiency and effectiveness
- Pathway redesign
- Active surveillance groups at high risk
- New technologies




WHY AREN'T PEOPLE BEING DIAGNOSED EARLY?



THERE ARE MANY REASONS INCLUDING:

- PATIENT FACTORS
- SYSTEM AND HEALTHCARE PROFESSIONAL FACTORS
- ISSUES WITH DIAGNOSTIC TESTS

UPTAKE OF BOWEL CANCER SCREENING IS POOR




- Bowel screening (gFOBT) is about 10 years old now, but uptake remains lower than other national screening programmes
- Bowel cancer mortality is 25% lower in those who've taken part in bowel screening (gFOBT)
- There are significant inequalities in uptake related to:
 - Deprivation
 - Sex (lower in men)
 - Age




REGIONAL VARIATION IN STAGE AT DIAGNOSIS

UNADJUSTED



ADJUSTED FOR CANCER TYPE



ADDITIONAL DRIVERS OF VARIATION



AGE


SOCIOECONOMIC FACTORS




Contains National Statistics data © Crown copyright and database right 2015. Contains OS data © Crown copyright and database right 2015.

WAITING TIMES FOR PATHOLOGY SERVICES ARE INCREASING

PATIENTS WAITING MORE THAN SIX WEEKS FOR PATHOLOGY DIAGNOSTICS AT QUARTER END



PATIENTS WAITING >12 WEEKS FOR PATHOLOGY DIAGNOSTICS AT QUARTER END




Source: NHS England Quarterly Diagnostic Waiting Times Statistics




Source: NHS England Quarterly Diagnostic Waiting Times Statistics

WE KNOW WE HAVE LESS IMAGING EQUIPMENT AND FEWER TRAINED STAFF IN THE UK

COMPUTED TOMOGRAPHY (CT) SCANNERS



MAGNETIC RESONANCE IMAGING (MRI)



Fewer trained radiologists

Per 1 000 000 inhabitants, 2013





A FASTER DIAGNOSIS STANDARD HAS BEEN SET



O TARGET 4 WEEKS MAX

Any patient referred for testing is definitively diagnosed/ cancer is excluded AND the result communicated to the patient, within four weeks.

AMBITION


- 95% of patients have this by 2020
- 50% definitively diagnosed within 2 weeks



THE ACE PROGRAMME

- A programme to accelerate, coordinate and evaluate (ACE) innovation and streamline diagnostic pathways to achieve earlier diagnosis of cancer.
- ACE 2 is piloting six projects trialling a new diagnostic pathway for patients with vague symptoms – an approach incorporating a Multidisciplinary Diagnostic Centre as in Denmark.

HOW MDC'S COULD IMPROVE EARLY CANCER DIAGNOSIS







THE POSSIBILITIES FOR EARLIER DIAGNOSIS

- Screening uptake
- Investment in additional capacity
- System efficiency and effectiveness
- Pathway redesign
- Active surveillance groups at high risk
- New technologies



THE POSSIBILITIES FOR EARLIER DIAGNOSIS

- Screening uptake
- Investment in additional capacity
- System efficiency and effectiveness
- Pathway redesign

16

- Active surveillance groups at high risk
- New technologies:
 - Circulating biomarkers CTCs, ctDNA, autoantibodies
 - Volatile compounds
 - Imaging, e.g. low-dose CT, ultrasound
 - Cell capture nasal, oesophageal brushings etc
 - Al/machine learning combining medical and nonmedical data sets



KEY POINTS: CANCER EARLIER DIAGNOSIS

The imperative

The possibilities

Consequences for patients and individuals

Implications for the health system



CONSEQUENCES FOR PATIENTS AND INDIVIDUALS

- False positives (e.g. LDCT 96%)
- False negatives
- Over-diagnosis (e.g. breast screening)
- Identifying tissue of origin



KEY POINTS: CANCER EARLIER DIAGNOSIS

The imperative

The possibilities

Consequences for patients and individuals

Implications for the health system



IMPLICATIONS FOR HEALTH SYSTEM

- Greater investment upstream new technologies, diagnostic capacity
- Shift in resource requirements downstream surgery vs treating metastatic disease
- Role of primary care:
 - Smaller? (Patients with known symptoms straight to test?
 - Larger? (Community based testing?)



IMPLICATIONS FOR HEALTH SYSTEM

- Greater investment upstream pe capacity
- Shift in resource rec vs treating m
- Role

- surgery

gies,

... Known symptoms – straight to

(Community based testing?)



LOOKING TO THE FUTURE – CRUK RESEARCH

- Understanding of early disease biology
- Biomarkers of disease:
 - Pre-cursors
 - Early cancers
- New imaging modalities
- Distinguishing lethal cancers that need treating from non-lethal ones which don't
- Use of Al/machine learning:
 - Radiology and pathology capacity (and accuracy?)
 - Investigation or presentation patterns



CANCER EARLIER DIAGNOSIS – POSSIBILITIES AND CONSEQUENCES

FOUNDATION FOR SCIENCE AND TECHNOLOGY DEBATE – 11 JULY 2017

Harpal Kumar, CEO CANCER RESEARCH UK

